Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189629 · ClinicalTrials.gov registry record · Phase 3
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
NCT02189629: Completed Phase 3 study, sponsored by Galderma R&D.
NCT02189629 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 453 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02189629, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
Study Summary
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
Primary Outcome
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (clear).
Interventions
- DRUG CD5789 (trifarotene)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2015-02-23 |
| Est. Completion | 2017-02-23 |
| Phase | Phase 3 |
What the finished NCT02189629 record still lists
NCT02189629 is an interventional study that assigns participants to a tested intervention. The registered 453 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 1 intervention - of which CD5789 (trifarotene) is the first listed.
NCT02189629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02189629 about?
NCT02189629 is a clinical study titled "CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris". Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
What is the current status of trial NCT02189629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2015-02-23. Estimated completion is 2017-02-23.
What interventions are being tested in trial NCT02189629?
The interventions under investigation include: CD5789 (trifarotene) (DRUG).
Who is sponsoring clinical trial NCT02189629?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02189629's enrollment target sits among peer trials
453 834th of 2000 higher than 1,166 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
- NCT05489211 · 454 participants · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI